discuss factor caus share fall jan
rais ep driven adjust
tax rate catalyst includ
newsflow lilli product competit threat remain
ew share
believ three key driver stock under-perform jan
drg index declin due presid trump state union drug
price critic share fell believ under-perform three
diabet drug sell side analyst question manag trulic
risk includ potenti threat novo oral semaglutid possibl
trulic rewind cardiovascular safeti studi demonstr cv
superior lower tax rate much investor
hope wake tax rate collaps chang tax rate
guidanc recal last friday lower tax rate
adjust ep follow lower tax
rate guidanc rais revenu guidanc
rang rais ep guidanc rang
catalyst view
readout primari complet dec accord clinicaltri gov
expect non-inferior placebo base upon cv
phase readout novo oral semaglutid
potenti competitor trulic inj await clariti efficaci
side effect profil
fda panel meet baricitinib autoimmun diseas ahead fda
action juli model odd approv
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
strateg updat regard anim health busi elanco conjunct
result juli
readout potenti novo victoza demonstr cv superior
trulic need well
galcanezumab cgrp fda action migrain prevent oct nda
outcom teva suit lilli cgrp migrain drug alleg patent
carolina top-lin readout potenti late expect superior
base case ep premium peer
mean due lilli better growth prospect ep compound-annual-growth-rate
vs group average off-set uncertainti around next key event
novo oral sema ph bari fda action
bull case ep
bull case ep
new product drive revenu upsid oper leverag rais ep
forecast price-to-earnings multipl expand competitor falter includ novo
semaglutid repres potenti addit upsid beyond bull case
base case ep
base case ep
see solid growth prospect balanc premium valuat new product
launch meet slightli exceed expect plan exit elanco
potenti value-enhanc competitor novo oral sema ph result
lilli bari fda action uncertainti
bear case ep
bear case ep
us revenu growth disappoint earn expect potenti
oral sema competitor data rais concern trulic long-term growth
bari reject fda trulic demonstr cv superior
rewind trial multipl contract due lower growth expect
enthusiasm new product momentum
balanc premium valuat
consensu expect lilli drive
signific oper margin expans
low base long-term
quarterli result financi guidanc
verzenio trulic jardianc taltz
fda action baricitinib arthriti mid-
pipelin news flow includ
extern busi develop
risk achiev price
upsid risk posit financi result
project new product revenu
forecast financi result upsid
product disappoint compel extern
downsid risk neg fda action
bari compet drug surpris upsid
financi result fall short expect
face us price pressur trial
exhibit new vs old consensu estim
price
price
price
valuat methodolog risk associ price target rate recommend referenc research report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres
morgan stanley research broadway attent research manag new york ny usa
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
valuat methodolog risk
pt base case ep premium peer mean
due lilli better growth prospect ep compound-annual-growth-rate vs group average off-set
risk achiev price target
upsid risk posit financi result project new product revenu
disappoint compel extern strateg action
downsid risk alimta patent invalid compet drug surpris
upsid financi result fall short expect face us price pressur
